Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Standard Biotools (LAB) EBT (2016 - 2025)

Standard Biotools (LAB) has disclosed EBT for 16 consecutive years, with $46.5 million as the latest value for Q4 2025.

  • Quarterly EBT rose 1854.09% to $46.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$30.9 million through Dec 2025, up 62.31% year-over-year, with the annual reading at -$28.2 million for FY2025, 57.41% up from the prior year.
  • EBT for Q4 2025 was $46.5 million at Standard Biotools, up from -$32.9 million in the prior quarter.
  • The five-year high for EBT was $46.5 million in Q4 2025, with the low at -$76.9 million in Q1 2022.
  • Average EBT over 5 years is -$21.0 million, with a median of -$20.8 million recorded in 2022.
  • The sharpest move saw EBT plummeted 275.08% in 2022, then surged 1854.09% in 2025.
  • Over 5 years, EBT stood at -$15.3 million in 2021, then tumbled by 36.1% to -$20.8 million in 2022, then soared by 165.84% to $13.7 million in 2023, then tumbled by 119.38% to -$2.7 million in 2024, then soared by 1854.09% to $46.5 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at $46.5 million, -$32.9 million, and -$18.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.